超凡蜘蛛侠

Family Dollar issues mass nationwide recall on toothpaste, vitamins, pain relievers and more_我的网站

A |     　　央广网北京8月26日消息(记者夏青)据中央广播电视总台经济之声报道，国内创新药审批又有新进展。    Variety discount store Family Dollar recently initiated multiple recalls on products ranging from over-the-counter drugs to toothpaste sold at regional chains in nearly two dozen states.The company first issued an announcement Oct. 5, which was published Oct. 10 by the U.S. Food and Drug Administration, alerting Family Dollar shoppers of a voluntary recall on "over-the-counter drugs and medical devices" that had been "stored outside of labeled temperature requirements by Family Dollar and inadvertently shipped" to some of its stores from June 1 through Sept. 21, 2023.The wide range of recalled items includes cold medicine, pain relievers, mouthwash, moisturizer, vitamins and more. Affected products were sold in 23 states from June 1 through Oct. 4, 2023."To date, Family Dollar has not received any consumer complaints or reports of illness related to this voluntary recall," the company statement read. "This recall is being conducted out of an abundance of caution."Family Dollar did not immediately respond to ABC News' request for comment.Click here to see the full list of products included in the recall and SKU information."Family Dollar has notified its affected stores asking them to check their stock immediately and to quarantine and discontinue the sale of any affected product," the company statement continued.Customers who purchased any of the recalled items are able to return them to the purchase location without a receipt for a refund.A full list of recalled items, as well as the states impacted, can be found on the FDA's website.Family Dollar experienced a similar issue earlier this spring when it voluntarily recalled seven Advil products that it said were also stored at the wrong temperature.。

B | 8月17日至23日，共有34款1类创新药首次在中国获批临床试验默示许可。

C | 还有一组更亮眼的数据：今年上半年，中国创新药对外授权共达成81笔合作，交易总额约1100亿美元，已经达到2025年全年总额的80%，再创历史同期新高。　　业内专家表示，这背后更重要的是中国创新药企角色的根本性转变。

D | 从过去的“原料供应商”，升级为与跨国药企平等对话、利益共享的“全球合伙人”。

E | 　　上半年科创板创新药企业绩亮眼　　创新药因研发难度大、附加值高，被誉为医药产业“皇冠上的明珠”。2026年上半年，科创板创新药企交出了漂亮“成绩单”。　　诺诚健华报告显示，上半年营收同比增长55.5%，达到11.4亿元，净利润2.4亿元，同比扭亏为盈。

F | 泽璟制药也交出上市以来首份盈利半年报，百济神州则交出史上最优半年度成绩单。

G | 　　“科创板创新药企业已经开始进入盈利兑现期。”苏商银行特约研究员武泽伟分析，“当前，创新药行业的商业化能力修复，海外权益合作持续落地，有效补充企业的运营现金流。国内审评与支付机制不断优化，缩短新药的上市周期，拓宽产品收入边界。

H | 依托完整的产业链红利，国内的生物医药配套体系日趋成熟，研发服务企业持续承接海内外订单，充分分享全球研发投入回暖带来的业务增量。”　　中国创新药对外授权交易额迭创新高　　中国创新药获得全球市场的认可。

I | 2025年全年，中国药企的对外授权潜在交易总金额高达1356.55亿美元，是2024年的两倍多，一举登顶全球首位。今年上半年，中国创新药对外授权交易总额约1100亿美元，达到了去年全年总额的八成，再创历史新高。

J | 　　国家药监局药品注册管理司副司长蓝恭涛介绍，中国在研新药数量约占全球30%，位列全球第二。中国医药产业创新效率居世界前列。　　蓝恭涛说：“2025年我国批准的11个新靶点、新机制药品中，4个是国产创新药，占比不到一半。今年上半年，我国批准的11个新靶点、新机制药品全都是自主研发的国产创新药。”　　中国药企正从“跟跑者”转变为“合作者”　　中国创新药实现了从“卖产品”到“卖技术”的跨越，中国创新药企业正在以“全球合作伙伴”的身份，与跨国药企联合开发、共享收益。　　武泽伟说：“未来，行业会逐步脱离同质化跟随研发，转向全新靶点与全新机制的源头创新。

K | 出海模式也从早期对外授权，过渡到自主完成海外申报与全球商业化运营。产业从产品出海升级为技术平台与研发体系的对外输出，整体国际竞争力稳步增强。”　　国家医保局近日发布《全民医疗保障“十五五”规划》，明确支持创新药纳入医保、推动商保创新药目录，释放强烈利好信号。　　中国医药创新促进会首席专家宋瑞霖说：“中国的创新药现在正处在一个历史性的崛起阶段，我们经历了从‘跟跑’到‘并跑’，现在我们正处于部分领域‘领跑’的阶段。大部分的跨国制药企业在未来的5年到10年都有一大批专利要到期，所以中国的创新药研究现在成为全球跨国制药企业争抢的目标。

Current article:http://www.shangfochengcongshuaizhuang.buzz/5pei4/cu2nn.docx

Published on:10:36:30